Company Overview of Celsus Therapeutics Plc
As of September 18, 2015, Celsus Therapeutics Plc was acquired by Akari Therapeutics, Plc, in a reverse merger transaction. Celsus Therapeutics Plc, a development stage biopharmaceutical company, engages in the discovery and development of non-steroidal, synthetic anti-inflammatory drugs. The company’s principal product candidate is MRX-6, a topical cream that is in Phase 2 clinical trial for the treatment of atopic dermatitis. Its product candidates in pre-clinical studies comprise OPT-1 for the treatment of conjunctivitis, post-operative inflammation, and/or dry eye; CFX-1 to treat cystic fibrosis; and OAX-1 for the treatment of osteoarthritis and other inflammatory diseases. The company w...
The Gridiron Building
One Pancras Square
London, N1C 4AG
Founded in 2004
Key Executives for Celsus Therapeutics Plc
Celsus Therapeutics Plc does not have any Key Executives recorded.
Celsus Therapeutics Plc Key Developments
Celsus Therapeutics Plc, Special/Extraordinary Shareholders Meeting, Sep 16, 2015
Aug 18 15
Celsus Therapeutics Plc, Special/Extraordinary Shareholders Meeting, Sep 16, 2015. Agenda: To approve private placement to raise about $70 million with a group of investors at about $1.58 per American Depositary Share, or $0.158 per ordinary share; and to approve acquisition of Volution Immuno Pharmaceuticals.
Celsus Therapeutics Plc Announces Board Changes
Jul 15 15
Effective as of immediately following Celsus Therapeutics Plc's annual general meeting of shareholders, Amos Eiran, formerly a Class B director of the board of directors of the company and Robert Francis Doman, formerly a Class A director of the board, were no longer serving as members of the board as they were not nominated for re-election by the board and their terms expired. Following the annual meeting, the compensation committee of the board is comprised of Mark Cohen, David Sidransky, M.D. and Johnson Lau, M.D., the nominating and governance committee of the board is comprised of Mark Cohen, Dr. Sidransky and Dr. Lau, and the audit committee of the board is comprised of Allan Shaw, Dr. Lau and Dr. Sidransky. As of the date of the annual meeting, Mr. Cohen no longer has the title executive chairman but remains as chairman of the board of directors. Because Mr. Cohen is not, and never has been an employee of the company, and based on his background, employment and affiliations, the board has determined that he qualifies as an independent director under NASDAQ Marketplace Rules.
Celsus Therapeutics Plc, Annual General Meeting, Jul 15, 2015
May 28 15
Celsus Therapeutics Plc, Annual General Meeting, Jul 15, 2015., at 13:00 US Eastern Standard Time. Location: 24 West 40 Street, 8 Floor. Agenda: To receive the accounts of the company for the year ended December 31, 2014 together with the report of the auditors of the company; to re-elect directors; and to re-appoint Kost, Forer Gabbay & Kasierer, a member of Ernst & Young Global, as auditors of Celsus to hold office until the conclusion of the next general meeting.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 13, 2015